OSLO, Norway, June 3, 2019 /PRNewswire/ -- Nordic Nanovector
ASA (OSE: NANO) announces that the European Patent Organisation
(EPO) has granted the company's European Patent covering the use of
Betalutin® or Humalutin® in combination with anti-CD20 antibodies
for the treatment of non-Hodgkin's lymphoma (NHL). The same patent
has also been issued in Japan,
China, Australia, Hong
Kong, Israel, Russia and Singapore while the patent is pending in USA,
Brazil, Canada, Indonesia, India, Korea, Mexico, New
Zealand, Philippines,
Ukraine and South Africa.
This patent is a result of Nordic Nanovector's continued focus
on securing intellectual property rights on its pipeline of novel
CD37-targeting drug candidates.
Patents covering Betalutin® and Humalutin®, as well as their
medical applications have already been granted in Europe, USA,
Canada, China, Hong
Kong, Australia,
Indonesia, Israel, Japan, Korea, Mexico, New
Zealand, Philippines,
Russia, Singapore, Ukraine and South
Africa. India, Brazil and Thailand are expected to be granted
soon.
Finally, two newer patent applications related to Betalutin®'s
clinical applications and combination with other drugs have also
been filed. The latest application has been made public on the 31
May under WO/2019/101789.
For further information, please contact:
IR enquiries
Malene Brondberg, VP Investor Relations and Corporate
Communications
Cell: +44-7561-431-762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible (Citigate Dewe Rogerson)
Tel: +44-207-638-9571
Email: nordicnanovector@citigatedewerogerson.com
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative
therapies to patients to address major unmet medical needs and
advance cancer care. The Company aspires to become a leader in the
development of targeted therapies for haematological cancers.
Nordic Nanovector's lead clinical-stage candidate is Betalutin®,
a novel CD37-targeting radioimmunotherapy designed to advance the
treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication
with substantial unmet medical need, representing a growing market
forecast to be worth nearly USD 29
billion by 2026. Nordic Nanovector intends to retain
marketing rights and to actively participate in the
commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
Forward-looking statements
This press release contains certain forward-looking
statements. These statements are based on management's current
expectations and are subject to uncertainty and changes in
circumstances, since they relate to events and depend on
circumstances that will occur in the future and which, by their
nature, will have an impact on Nordic Nanovector's business,
financial condition and results of operations. The terms
"anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans",
"should", "projects", "targets", "will", "would" or, in each case,
their negative, or other variations or comparable terminology are
used to identify forward-looking statements. These forward-looking
statements are not historic facts. There are a number of factors
that could cause actual results and developments to differ
materially from those expressed or implied in the forward-looking
statements. Factors that could cause these differences include, but
are not limited to, risks associated with implementation of Nordic
Nanovector's strategy, risks and uncertainties associated with the
development and/or approval of Nordic Nanovector's product
candidates, ongoing and future clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology
changes and new products in Nordic Nanovector's potential market
and industry, Nordic Nanovector's freedom to operate (competitors
patents) in respect of the products it develops, the ability to
develop new products and enhance existing products, the impact of
competition, changes in general economy and industry conditions,
and legislative, regulatory and political factors. No assurance can
be given that such expectations will prove to have been correct.
Nordic Nanovector disclaims any obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise.
This information is subject to a duty of disclosure pursuant
to Section 5-12 of the Securities Trading Act.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/nordic-nanovector/r/nordic-nanovector--european-patent-granted-for-betalutin--or-humalutin--in-combination-with-anti-cd2,c2830523